Home
Regulatory UpdatesSep 9, 2026•1 min read

Korea MFDS Expands GIFT Review to Include Patient Experience Data

By the PharmaCountry team

The Korean MFDS revised its GIFT fast‑track guidelines, permitting patient‑reported symptoms, quality‑of‑life data, preferences, interviews, videos and written opinions as reference material for priority review of rare disease drugs.

On the 28th, the Ministry of Food and Drug Safety (MFDS) under Director‑General Oh Yu‑kyung announced a revision to the guidance for priority‑review designation applications. The amendment allows patient experience data—such as self‑reported symptoms, quality‑of‑life measures, treatment preferences, patient and caregiver interviews, patient‑generated videos, and written comments—to be used as reference material in the evaluation of Global Innovation Products Fast‑Track (GIFT) designation for rare and severe disease therapies. This change aims to capture real‑world patient perspectives that are difficult to reflect through clinical trial metrics alone, enhancing the assessment process for innovative treatments.

Compiled by the PharmaCountry team · Source: KPA News

More articles

View all insights